Tenaya Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Faraz Ali
- Full Time Employees
- 70
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 171 Oyster Point Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Jul 30, 2021
- CIK
- 0001858848
- Website
- tenayatherapeutics.com
- Similar Companies
- Business
- Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company that discovers, develops and delivers curative therapies addressing the underlying drivers of heart disease through gene therapy, cellular regeneration and precision medicine platforms; its lead programs include TN-201, an AAV9-based gene therapy delivering a functional MYBPC3 gene via single intravenous infusion for MYBPC3-associated hypertrophic cardiomyopathy (HCM), which has received FDA Fast Track, Orphan Drug and Rare Pediatric Drug designations as well as European Commission orphan medicinal product designation and is in the ongoing MyPEAK-1 Phase 1b/2 trial reporting interim data showing tolerability, transduction and MyBP-C increases; TN-401, an AAV9-based gene therapy delivering a functional PKP2 gene for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), with FDA Fast Track and Orphan Drug designations plus European orphan status and initial Phase 1b RIDGE-1 data anticipated in late 2025; and TN-301, a selective small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF) and related cardio-muscular conditions, demonstrating safety, pharmacokinetics and target engagement in Phase 1 with preclinical benefits in cardiac function, inflammation and fibrosis. Founded in 2016 and headquartered at 171 Oyster Point Boulevard in South San Francisco, California, the company targets rare genetic cardiomyopathies and prevalent heart conditions with integrated capabilities in target validation, capsid engineering and manufacturing; it operates primarily in the United States with clinical trials also in the United Kingdom and maintains multiple preclinical programs using gene addition, editing, silencing and cellular regeneration approaches. Recent developments include presentation of deeper, durable MyPEAK-1 Cohort 1 data and initial Cohort 2 results at the 2025 American Heart Association Scientific Sessions indicating consistent hypertrophy improvements and dose-responsive transduction for TN-201; a $25 million common stock investment by The Column Group in March 2025 acquiring 35.7 million shares at $0.70 each; an $8 million grant from the California Institute for Regenerative Medicine supporting the RIDGE-1 TN-401 study; announcement of 2025 priorities emphasizing pipeline advancement; stock option repricing for CEO Faraz Ali and employees affecting 4.1 million shares at $1.21 exercise price; and plans for a public offering of common stock and pre-funded warrants.
Company News
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript
Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026
Financial Survey: Tenaya Therapeutics (NASDAQ:TNYA) versus Belite Bio (NASDAQ:BLTE)
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update